{
  "nctId": "NCT03577171",
  "briefTitle": "A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)",
  "officialTitle": "A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B",
  "protocolDocument": {
    "nctId": "NCT03577171",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2018-06-18",
    "uploadDate": "2020-12-01T15:47",
    "size": 1212759,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03577171/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "TRIPLE",
  "enrollmentInfo": {
    "enrollmentCount": 25,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2018-06-19",
    "completionDate": "2019-06-21",
    "primaryCompletionDate": "2019-06-21",
    "firstSubmitDate": "2018-06-06",
    "firstPostDate": "2018-07-05"
  },
  "eligibilityCriteria": {
    "criteria": "Key Inclusion Criteria:\n\n* Male or female between ages 18 and 70 years\n* HBeAg-positive at screening\n* In good general health except for cHBV\n* HBV viral load ≥2×105 IU/mL\n* Hepatitis B surface antigen (HBsAg) \\>1000 IU/mL at screening\n\nKey Exclusion Criteria:\n\n* Any prior treatment with lamivudine or telbivudine, previous treatment with an investigational agent for HBV other than ABI-H0731; or any other SOC treatment for \\>4 weeks\n* Co-infection with HIV, hepatitis C virus (HCV), hepatitis E virus (HEV) or hepatitis D virus (HDV)\n* History or evidence of hepatic decompensation (including gastrointestinal bleeding or esophageal varices) at any time prior to or at time of screening\n* Clinically significant cardiac or pulmonary disease, chronic or recurrent renal or urinary tract disease, liver disease other than HBV, endocrine disorder, autoimmune disorder, diabetes mellitus requiring treatment with insulin or hypoglycemic agents, neuromuscular, musculoskeletal, or mucocutaneous conditions requiring frequent treatment, seizure disorders requiring treatment, or other medical conditions requiring frequent medical management or pharmacologic or surgical treatment that in the opinion of the Investigator or the Sponsor makes the participant unsuitable for the study\n* Previous treatment with an investigational agent for HBV other than ABI-H0731 in the last 6 months before screening\n* History of hepatocellular carcinoma (HCC)\n* Females who are lactating or pregnant or wish to become pregnant are excluded from the study\n* Exclusionary laboratory parameters at screening:\n\n  * Platelet count \\<100,000/mm3\n  * Albumin \\<lower limit of normal (LLN)\n  * Direct bilirubin \\>1.2×upper limit of normal (ULN)\n  * Alanine aminotransferase (ALT) \\>10×ULN at screening\n  * Serum alpha fetoprotein (AFP) ≥100 ng/mL. If AFP at Screening is \\>ULN but \\<100 ng/mL, participant is eligible if a hepatic imaging study prior to the initiation of study drug reveals no lesions suspicious of possible HCC\n  * International Normalized Ratio (INR) \\>1.5×ULN\n  * Glomerular filtration rate (GFR) \\<60 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "70 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Mean log10 HBV DNA From Baseline (Day 1) to Week 12 or Week 24 on ABI H0731 + SOC ETV as Compared to Placebo + SOC ETV",
        "description": "Hepatitis B virus (HBV) DNA was measured using COBAS TaqMan Version 2.0. The lower limit of quantitation (LLOQ) was 20 IU/mL and the limit of detection (LOD) was 10 IU/mL.",
        "timeFrame": "Baseline, Week 12, and Week 24"
      }
    ],
    "secondary": [
      {
        "measure": "Number of Participants One or More Adverse Events",
        "timeFrame": "Up to Follow-up (maximum up to Week 36)"
      },
      {
        "measure": "Number of Participants With Premature Study Discontinuation",
        "timeFrame": "Up to Follow-up (maximum up to Week 36)"
      },
      {
        "measure": "Number of Participants With One or More Abnormal Safety Laboratory Result",
        "timeFrame": "Up to Week 36"
      },
      {
        "measure": "Number of Participants With a Clinically-significant Electrocardiogram Abnormality",
        "timeFrame": "Up to Week 24"
      },
      {
        "measure": "Number of Participants With a Clinically-significant Change in Vital Signs",
        "description": "Vital signs assessed were body temperature, respiratory rate, and pulse rate",
        "timeFrame": "Baseline and up to Week 24"
      },
      {
        "measure": "Number of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Have Normal ALT at Week 24 on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV",
        "timeFrame": "Baseline to Week 24"
      },
      {
        "measure": "Number of Participants With a Decline in Viral DNA to Below Limit of Quantitation on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV",
        "description": "HBV DNA was measured using COBAS TaqMan Version 2.0. The LLOQ was 20 IU/mL and the LOD was 10 IU/mL. The number of participants with HBV DNA below the limit of quantitation (\\<20 IU/mL) and target detected (≥10 IU/mL) was assessed.",
        "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24"
      },
      {
        "measure": "Median Time to Viral Suppression, Defined as HBV DNA <20 IU/mL, on ABI-H0731 + ETV as Compared to Placebo + ETV",
        "description": "Median time to viral suppression will be calculated and evaluated between participants on ABI-H0731 + ETV as compared to placebo + ETV.",
        "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24"
      },
      {
        "measure": "Number of Participants With Emergence of Resistant HBV Variants on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV",
        "description": "Emergence of a resistant HBV variant was defined as an increase of ≥1 log10 IU/mL from the nadir in HBV DNA.",
        "timeFrame": "Up to Week 36"
      },
      {
        "measure": "Trough Levels of ABI-H0731 on ABI-H0731 + SOC ETV Therapy",
        "timeFrame": "Before dosing at Baseline (Day 1), Weeks 2, 4, 12, and 24"
      },
      {
        "measure": "Trough Levels of ETV on ABI-H0731 + ETV Therapy as Compared With Placebo + ETV Therapy",
        "timeFrame": "Before dosing at Baseline (Day 1), Weeks 2, 4, 12, and 24"
      },
      {
        "measure": "Trough to Peak Ratios of ABI-H0731 on ABI-H0731 + ETV Therapy",
        "timeFrame": "Baseline, Weeks 2, 4, 12, and 24"
      },
      {
        "measure": "Trough to Peak Ratios of ETV on ABI-H0731 + ETV Therapy as Compared With Placebo + ETV Therapy",
        "timeFrame": "Baseline, Weeks 2, 4, 12, 24, and 28"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 13,
      "otherCount": 0,
      "totalCount": 14
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:25.502Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}